Erli Plus (12.5/500mg) 14 Tablets
Combination of Empagliflozin and Metformin for glycemic control in type 2 diabetes.
Erli Plus is a fixed-dose combination of empagliflozin and metformin hydrochloride. Empagliflozin is an SGLT2 inhibitor that increases urinary glucose excretion, while metformin reduces hepatic glucose production and improves insulin sensitivity. Together, they provide superior glycemic control for adults with type 2 diabetes mellitus compared to either agent alone.
Purpose
Improvement of glycemic control in adults with type 2 diabetes mellitus.
Ingredients
Empagliflozin and Metformin Hydrochloride; strengths as per approved formulation.
Warnings
Rare but serious risk of lactic acidosis. Monitor kidney function regularly. Discontinue before iodinated contrast procedures.
Side Effects
Urinary tract infections, yeast infections, diarrhea, and nausea. Risk of lactic acidosis due to metformin.
Storage Instructions
Store below 30°C in a dry place. Protect from moisture.
| Brand | Pharmevo |
| Status | Active |
Related Products
